Albemarle Corporation $ALB Stock Purchased by Phoenix Financial Ltd.

Phoenix Financial Ltd. grew its stake in shares of Albemarle Corporation (NYSE:ALB – Free Report) by 1,034.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,429 shares of the specialty chemicals company’s stock after acquiring an additional 15,892 shares during the period. Phoenix Financial Ltd.’s holdings in Albemarle were worth $1,844,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ALB. Sigma Planning Corp grew its position in shares of Albemarle by 2.3% in the first quarter. Sigma Planning Corp now owns 2,952 shares of the specialty chemicals company’s stock valued at $530,000 after purchasing an additional 66 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Albemarle by 0.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 11,664 shares of the specialty chemicals company’s stock worth $2,082,000 after purchasing an additional 75 shares during the period. Cadence Wealth Management LLC lifted its holdings in Albemarle by 1.8% during the 1st quarter. Cadence Wealth Management LLC now owns 4,982 shares of the specialty chemicals company’s stock worth $894,000 after purchasing an additional 87 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in Albemarle by 7.0% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,584 shares of the specialty chemicals company’s stock worth $214,000 after purchasing an additional 103 shares during the last quarter. Finally, Parallel Advisors LLC lifted its holdings in Albemarle by 4.9% during the 1st quarter. Parallel Advisors LLC now owns 2,588 shares of the specialty chemicals company’s stock worth $465,000 after purchasing an additional 120 shares during the last quarter. 92.87% of the stock is currently owned by institutional investors and hedge funds.

Albemarle Stock Performance

NYSE:ALB opened at $93.62 on Monday. The company has a market cap of $11.05 billion, a price-to-earnings ratio of 22.61, a PEG ratio of 0.59 and a beta of 1.34. Albemarle Corporation has a fifty-two week low of $89.77 and a fifty-two week high of $221.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.57 and a current ratio of 2.34. The stock has a fifty day moving average price of $103.61 and a 200-day moving average price of $145.56.

Albemarle (NYSE:ALB – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.52 billion. Albemarle had a return on equity of 14.91% and a net margin of 10.40%. Albemarle’s revenue was up 18.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.19) earnings per share. As a group, equities analysts anticipate that Albemarle Corporation will post 10.64 EPS for the current fiscal year.

Albemarle Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Friday, December 18th will be paid a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Friday, December 18th. Albemarle’s dividend payout ratio is presently 39.61%.

Wall Street Analysts Forecast Growth

ALB has been the subject of several recent research reports. JPMorgan Chase & Co. reduced their price target on Albemarle from $160.00 to $140.00 and set a “neutral” rating for the company in a research note on Tuesday, August 25th. Morgan Stanley lowered their price objective on Albemarle from $161.00 to $105.00 and set an “equal weight” rating on the stock in a research report on Monday, November 9th. Bank of America dropped their target price on Albemarle from $131.00 to $120.00 in a report on Thursday. Robert W. Baird dropped their target price on Albemarle from $157.00 to $123.00 in a report on Wednesday, October 14th. Finally, Truist Financial reissued a “buy” rating and issued a $170.00 target price (down from $185.00) on shares of Albemarle in a research report on Friday, November 6th. Fifteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $152.63.

Read Our Latest Stock Report on ALB

About Albemarle

(Free Report)

Albemarle Corporation is a specialty chemicals company that produces lithium, bromine and refining catalysts. Its products serve industries including energy storage, transportation, electronics, petroleum refining and pharmaceuticals. The company supplies lithium compounds used in rechargeable batteries and other applications. It also makes bromine-based products for uses such as flame retardants and water treatment, along with catalysts used in refining petroleum. Albemarle traces its history to 1887 and is headquartered in Charlotte, North Carolina.

Featured Articles

Want to see what other hedge funds are holding ALB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albemarle Corporation (NYSE:ALB – Free Report).

Institutional Ownership by Quarter for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.